A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. (Q38395319)
Jump to navigation
Jump to search
scientific article published on September 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. |
scientific article published on September 2007 |
Statements
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors (English)
M Candelaria
D Gallardo-Rincón
C Arce
L Cetina
J L Aguilar-Ponce
A González-Fierro
A Chávez-Blanco
E de la Cruz-Hernández
M F Camargo
C Trejo-Becerril
E Pérez-Cárdenas
L Taja-Chayeb
T Wegman-Ostrosky
A Revilla-Vazquez
A Dueñas-González
1 September 2007